ArticleAdvanced pharmaceutical bulletin2013
Skin infection management using novel antibacterial agents.
Article in Advanced pharmaceutical bulletin, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Electrosprayed Nanoparticles Containing Hydroalcoholic Extract ofAdvanced pharmaceutical bulletin · 2023Article
- Green synthesis and antibacterial effects of aqueous colloidal solutions of silver nanoparticles using camomile terpenoids as a combined reducing and capping agent.Bioprocess and biosystems engineering · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) cause difficulties in the management of skin and soft tissue infections and have led to morbidity and mortality in hospital-acquired infections especially in susceptible individuals, those who are generally sick or immunosuppressed. Currently approaches in antibacterial agents offer opportunities to manage the trouble using novel anti-infection systems. Therefore, nanotechnology, a most promising field for generating new applications in medicine, has introduced a most prominent nanoproduct named as nanosilver that revealed excellent antimicrobial activity against some of the hazardous infections. Also cathelicidin peptides which are a part of native immune defense system in the skin and epithelia exhibit excellent antimicrobial activity against some of these perilous infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.